Literature DB >> 15911816

Short-term paroxetine treatment does not alter the motor response to levodopa in PD.

Kathryn A Chung1, Nichole E Carlson, John G Nutt.   

Abstract

The authors examined the motor effects of 2 weeks of paroxetine, a serotonin reuptake inhibitor (SSRI), and placebo on responses to 2-hour levodopa infusions in 14 subjects with Parkinson disease. Paroxetine did not affect tapping scores or dyskinesia. Baseline walking speed (preinfusion) increased on paroxetine, often associated with an increased subjective perception of worsened balance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15911816     DOI: 10.1212/01.WNL.0000161841.41885.80

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

1.  Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients.

Authors:  Maurits E L Arbouw; Kris L L Movig; Cees Neef; Henk-Jan Guchelaar; Toine C G Egberts
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

Review 2.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 3.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

4.  Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.

Authors:  Christopher Bishop; Jessica A George; William Buchta; Adam A Goldenberg; Mohamed Mohamed; Sando O Dickinson; Satie Eissa; Karen L Eskow Jaunarajs
Journal:  Eur J Neurosci       Date:  2012-07-05       Impact factor: 3.386

5.  Motor priming in neurorehabilitation.

Authors:  Mary Ellen Stoykov; Sangeetha Madhavan
Journal:  J Neurol Phys Ther       Date:  2015-01       Impact factor: 3.649

6.  The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.

Authors:  Wei-Li Kuan; Jing-Wei Zhao; Roger A Barker
Journal:  Psychopharmacology (Berl)       Date:  2007-12-23       Impact factor: 4.530

Review 7.  Therapeutic potential of fluoxetine in neurological disorders.

Authors:  Jop P Mostert; Marcus W Koch; Marco Heerings; Dorothea J Heersema; Jacques De Keyser
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

8.  Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.

Authors:  Melissa M Conti; Corinne Y Ostock; David Lindenbach; Adam A Goldenberg; Elias Kampton; Rich Dell'isola; Aaron C Katzman; Christopher Bishop
Journal:  Neuropharmacology       Date:  2013-09-22       Impact factor: 5.250

Review 9.  Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?

Authors:  G Linazasoro; N Van Blercom; L Ugedo; J A Ruiz Ortega
Journal:  J Neural Transm (Vienna)       Date:  2008-02-04       Impact factor: 3.575

Review 10.  The Human Experience with Intravenous Levodopa.

Authors:  Shan H Siddiqi; Natalia K Abraham; Christopher L Geiger; Morvarid Karimi; Joel S Perlmutter; Kevin J Black
Journal:  Front Pharmacol       Date:  2016-01-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.